-
European expert panel recommends Hexvix
Despite considerable positive evidence, the use of Hexvix has historically differed widely from country to country and between clinics. European recommendations from a consensus group have now been published, which may make the use of Hexvix-guided fluorescence cystoscopy more unison in Europe.
>> Read more22.04.10 -
NorDiag's kick start for an exciting 2010
NorDiag's strong growth for the Company's core business continued in 2009, giving a total operating revenue growth of 43 % for 2009 compared to 2008. The restructuring of the Company is completed and the operation is financially secured towards a break-even quarter in 2011. "2010 will be an exciting year for NorDiag," comments CEO Mårten Wigstøl.
>> Read more19.02.10 -
A transformational year for Algeta ASA
"2009 was a transformational year for Algeta during which we successfully delivered a number of major milestones in progressing towards our objective of creating a focused oncology company," said Andrew Kay, Algeta's President and CEO. The results for the last quarter and full year 2009 were presented in Oslo Friday.
>> Read more19.02.10 -
NorDiag: Cooperation agreement with Molzym
NorDiag and Molzym have combined their techno-logies into an integrated system for automated molecular detection of pathogens, among others for sepsis testing. The companies have signed a collaboration agreement regarding sale of an integrated solution for sepsis testing and more.
>> Read more17.02.10 -
"A major milestone for NorDiag ASA"
NorDiag ASA and Hain Lifescience GmbH have entered into an OEM agreement for the Arrow instrument and for sample preparation reagents to be used in connection with Hain Lifescience molecular biological assays. "This is a major milestone for the Company," says CEO of NorDiag Mårten Wigstøl (pictured).
>> Read more15.02.10 -
DiaGenic and Ferrer inCode Sign Distribution Agreement
DiaGenic ASA and Ferrer inCode have signed a distribution agreement for the blood-based ADtect test for early diagnosis of Alzheimer’s disease covering a total of 32 countries. The agreement gives Ferrer inCode the exclusive right to sell and market ADtect initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy, Spain and Portugal followed by Latin America.
>> Read more21.01.10 -
Nutri Pharma ASA launches offer for Bionor Immuno AS
Nutri Pharma ASA has submitted a voluntary exchange offer for all outstanding shares in Bionor Immuno AS. The shareholders of Bionor will be offered 1 Nutri Pharma share per 2 shares in Bionor Immuno AS. -- We are very excited about the prospects, says Trond Syvertsen (picture), CEO of Nutri Pharma ASA.
>> Read more19.01.10 -
Algeta and IFE agree to collaborate
Algeta ASA, the cancer therapeutics company, and the Institute for Energy Technology (IFE), the international research institute for energy and nuclear technology based in Oslo, have agreed to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials.
>> Read more18.01.10 -
FDA Advisory Committee recommends Hexvix
The FDAs Oncologic Drugs Advisory Committee (ODAC) has recommended Photocure's pharmaceutical product Hexvix as an adjunct to white light cystoscopy in the detection of non-muscle invasive papillary cancer of the bladder.
>> Read more18.12.09 -
Superba Krill Oil ready for the European market
Aker BioMarine has been notified by the Finnish Food Safety Authority that Superba™ Krill Oil is now approved as Novel Food in the European Union. Consequently, Superba™ Krill Oil can be sold in all countries within the European Union.
>> Read more17.12.09
Norwegian Bioindustry Association
Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98